Enter a world where precision meets innovation. TALOX is a new AI oncology company dedicated to decoding drug resistance.  We believe that the best way to treat patients is to study patients. We are training a new AI model called MINERVA with clinical, pathological, genomic, spatial transcriptomic and spatial proteomic data from thousands of patients resistant to ADCs (antibody drug conjugates).  As ADCs are the fastest growing therapy in oncology, unfortunately most patients won't respond, highlighting the need for predicting resistance and providing therapeutic options.  As we train MINERVA to identify new targets we will build those targets into therapies with the ultimate goal of getting these to the patients that need them.